The stock of XBiotech Inc. (NASDAQ:XBIT) is a huge mover today! The stock decreased 1.59% or $0.14 during the last trading session, reaching $8.66. About 95,697 shares traded. XBiotech Inc. (NASDAQ:XBIT) has declined 7.38% since February 16, 2018 and is downtrending. It has underperformed by 7.38% the S&P500.
The move comes after 6 months negative chart setup for the $310.20 million company. It was reported on Feb, 16 by Barchart.com. We have $8.23 PT which if reached, will make NASDAQ:XBIT worth $15.51M less.
More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Globenewswire.com which released: “XBiotech Highlights Quarterly Developments Nasdaq:XBIT – GlobeNewswire” on August 10, 2018, also Seekingalpha.com with their article: “XBiotech’s bermekimab successful in mid-stage dermatitis study – Seeking Alpha” published on December 12, 2018, Globenewswire.com published: “XBiotech Highlights Third Quarter Developments for 2018 Nasdaq:XBIT – GlobeNewswire” on October 31, 2018. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Globenewswire.com and their article: “XBiotech Announces Successful Completion of GMP Audit – GlobeNewswire” published on December 03, 2018 as well as Globenewswire.com‘s news article titled: “Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain – GlobeNewswire” with publication date: January 23, 2019.
– Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $310.20 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.